Bio Pharma Dive
JUNE 11, 2025
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
Rethinking Clinical Trials
JUNE 11, 2025
Stephanie Morain, Nancy Kass, and Ruth Faden In this Friday’s Rethinking Clinical Trials Grand Rounds, Stephanie Morain, Nancy Kass, and Ruth Faden will present “Fit for Purpose: Improving the Ethical Oversight of Pragmatic Clinical Trials.” The live webinar will be held on Friday, June 13, 2025, at 1:00 pm eastern. Morain is an associate professor of health policy and management in the Bloomberg School of Public Health and a core faculty member at the Berman Institute of Bioet
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 11, 2025
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.
Scienmag
JUNE 11, 2025
CAMBRIDGE, MA — As more connected devices demand an increasing amount of bandwidth for tasks like teleworking and cloud computing, it will become extremely challenging to manage the finite amount of wireless spectrum available for all users to share. Engineers are employing artificial intelligence to dynamically manage the available wireless spectrum, with an eye toward reducing latency and boosting performance.
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
NY Times
JUNE 11, 2025
Skip to content Skip to site index Today’s Paper Opinion | It’s Code Red for Vaccines [link] Share full article 205 205 Advertisement SKIP ADVERTISEMENT You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load. Opinion Supported by SKIP ADVERTISEMENT Guest Essay It’s Code Red for Vaccines June 11, 2025, 5:03 a.m.
Scienmag
JUNE 11, 2025
image: Researchers who carried out the study view more Credit: Universidad de Córdoba Vegetation vigor demonstrates that the Sierra Nevada mountain range’s ancient irrigation channels affect soil moisture levels From satellite images taken over a period of 26 years, a team at the UCO shows how a system of irrigation channels dating back to the Roman Empire increases the water content of the soil adjacent to them The Sierra Nevada Natural Park is traversed by more than 700 km of channels dug int
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Scienmag
JUNE 11, 2025
image: Heatmap of Overall Hospital Rating Star Rating Across States. view more Credit: Hung et al., 2025, PLOS One, CC-BY 4.0 ( A new study analyzing more than 3,200 hospitals across the United States (U.S.) has revealed stark differences in how patients rate their hospital experiences depending on where they receive care. The research was published June 11, 2025 in the open-access journal PLOS One and led by Man Hung of the University of Utah, U.S., and colleagues.
ACRP blog
JUNE 11, 2025
In the midst of this Pride Month, current politically motivated headwinds may be driving some of the terminology related to inclusive research underground, but the scientific rationale for inclusive studies is here to stay because “smart science is smart business,” says a presenter from ACRP 2025. Addressing issues surrounding sexual gender minority (SGM) health inequities and the importance of collecting sexual orientation and gender identity (SOGI) data during clinical trials, Meghan McKenzi
Scienmag
JUNE 11, 2025
SAN ANTONIO, June 11, 2025 – Showing its leadership in addressing the opioid crisis, the UT Health San Antonio Multispecialty and Research Hospital is the state’s first to approve use of a new non-opioid medication for pain following orthopaedic and podiatric surgeries. The effort is part of UT Health San Antonio’s “multimodal” approach to pain management, combining non-opioid medications and physical therapy, at its hospital that opened Dec. 10 to provide specialty surgery, advanced imaging and
XTalks
JUNE 11, 2025
The global biologics market is experiencing significant growth, projected to reach $732.4 billion by 2030, up from $421.1 billion in 2023, with a compound annual growth rate (CAGR) of 8.2%. This surge underscores the increasing demand for efficient, cost-effective manufacturing processes, particularly in early-phase clinical programs. As biologics developers accelerate timelines for first-in-human (FIH) clinical programs, the need for streamlined, flexible downstream processes is intensifying.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
The Pharma Data
JUNE 11, 2025
FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a significant regulatory milestone from the U.S. Food and Drug Administration (FDA). The agency has officially approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five of its previously approved indications.
Pharma Times
JUNE 11, 2025
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Bimekizumab shows lasting efficacy at EULAR 2025 by John Pinching | 11th Jun 2025 | News Three-year data highlights inflammation control in psoriatic arthritis UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthri
The Pharma Data
JUNE 11, 2025
Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) has announced the dosing of the first patient in the Phase 3 REVEAL clinical trial, marking a significant milestone in the development of ION582, an investigational therapy for Angelman syndrome (AS).
STAT News
JUNE 11, 2025
Europe’s comparatively cautious approach to food additives is the envy of health secretary Robert F. Kennedy Jr. and the Make America Healthy Again movement. A Texas bill now before Gov. Greg Abbott aims to help close the gap by slapping warning labels on foods that contain any of 44 additives and dyes. Abbott has not said whether he intends to sign Senate Bill 25 into law.
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Scienmag
JUNE 11, 2025
Lipids are essential components of cancer cells due to their structural and signalling roles 1. To meet metabolic demands, many cancers take up extracellular lipids 2 , 3 , 4 ,5 ; however, how these lipids contribute to cancer growth and progression remains poorly understood. Here, using functional genetic screens, we identify uptake of lipoproteins—the primary mechanism for lipid transport in circulation—as a key determinant of ferroptosis sensitivity in cancer.
STAT News
JUNE 11, 2025
In December 2023, a groundbreaking announcement grabbed headlines : After years of anticipation, the Food and Drug Administration approved the first gene therapies for treating sickle cell disease, offering hope of eliminating life-altering symptoms. News at the time also featured the treatment’s prohibitive cost — between $2 and $3 million per person.
The Pharma Data
JUNE 11, 2025
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP) at the 2025 Annual Congress of the European Alliance of Associations for Rheumatology (EULAR) in Barcelona, Spain.
Pharma Marketing Network
JUNE 11, 2025
Pharmaceutical marketing has always been a dynamic force within the healthcare ecosystem. In 2025, the pace of change is faster than ever, driven by innovations in digital technology, new regulatory landscapes, and shifting expectations among healthcare providers and patients alike. So what exactly is pharmaceutical marketing today, and how is it adapting to meet tomorrow’s challenges?
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Scienmag
JUNE 11, 2025
Promising results of a presurgical combination for lung cancer Novel insights into multiple myeloma and CAR NK cell function New therapeutic strategies for glioblastoma and BRCA-deficient cancers HOUSTON, June 11, 2025 ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
STAT News
JUNE 11, 2025
As a transfusion medicine physician, I have encountered increasing requests for blood from Covid-19 unvaccinated donors or directed donations based on personal beliefs. In one case, a patient refused transfusion from the standard donor pool — insisting on receiving only blood from unvaccinated individuals — and ultimately experienced severe complications during surgery due to delayed transfusion, despite multiple consults and clear explanations that vaccination status has no impact
Scienmag
JUNE 11, 2025
image: Neuroimaging research lead prepares MRI scanner for child brain imaging study. view more Credit: Rebecca M. Lee and Abid Fahim, CC0 ( using images from kalhh ( and Pixabay, CC0 ( In a study of 34 children, the volumes of part of the brain known as the basal ganglia differed significantly between children whose parents were pregnant with them during Superstorm Sandy versus children without prenatal Sandy exposure.
STAT News
JUNE 11, 2025
The new agency at the center of health secretary Robert F. Kennedy Jr.’s agenda is hitting its first hurdle: Congress. The administration’s sweeping reorganization plan for the Department of Health and Human Services would shrink the National Institutes of Health and slash a litany of disease prevention programs while making the Administration for a Healthy America a new crown jewel of the agency, focused on chronic disease.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The Pharma Data
JUNE 11, 2025
argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases, presented encouraging new clinical data at the 2025 European Congress of Rheumatology (EULAR), held June 11–14 in Barcelona, Spain. The data come from Phase 2 trials evaluating its investigational therapy VYVGART® (efgartigimod) for two hard-to-treat autoimmune conditions: idiopathic inflam
Pharmaceutical Technology
JUNE 11, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
PharmTech
JUNE 11, 2025
News All News Bio/Pharma News Publications All Publications PharmTech PharmTech Europe Resources Marketplace ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management Peer-Reviewed Research PharmTech Products Pharma Insights Sponsored Podcasts Sponsored Videos Sponsored eBooks Whitepapers Webcasts Multimedia All Videos Ask the Expert Behind The Headlines Buy, Sell, Hold Drug Digest Videos Drug Solutions Podcast Peer Exchange Sexy Science Tech Talk Conference Conference Coverage Confer
NPR Health - Shots
JUNE 11, 2025
For nearly 15 years, Dennis Burton worked on creating an HIV vaccine considered to be one of the leading vaccine efforts. In late May, he learned the Trump administration was ending the project.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Pharma Data
JUNE 11, 2025
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the pivotal Phase 3 POETYK PsA-1 trial, reinforcing the potential of its oral, selective TYK2 inhibitor, Sotyktu® (deucravacitinib) , as an effective treatment for adults with active psoriatic arthritis (PsA).
Pfizer
JUNE 11, 2025
TRIMTECH Therapeutics carterda Wed, 06/11/2025 - 16:56 Active Portfolio Companies Trimtech Therapeutics is developing selective small molecule degraders of toxic protein aggregates for treatment of neurodegenerative and peripheral diseases, while leaving functional monomers untouched. The company’s proprietary degrader technology leverages TRIM21 biology as pioneered by the company’s founders Dr Leo James and Dr Will McEwan from the University of Cambridge.
Bio Pharma Dive
JUNE 11, 2025
Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several HIV studies.
NPR Health - Shots
JUNE 11, 2025
A study from JAMA Pediatrics compares states that have permissive gun laws with others that have strict regulations. The states with tougher rules did not see a rise in gun deaths among children and teens.
Expert insights. Personalized for you.
236 
Let's personalize your content